Home > Research > Publications & Outputs > Desflurane in modern anaesthetic practice

Electronic data

  • Desflurane in modern anaesthetic practice- walking on thin ice(caps) - accepted version

    Rights statement: This is the author’s version of a work that was accepted for publication in British Journal of Anaesthesia. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in British Journal of Anaesthesia, 125, 6, 2020 DOI: 10.1016/j.bja.2020.09.013

    Accepted author manuscript, 245 KB, PDF document

    Embargo ends: 7/10/21

Links

Text available via DOI:

View graph of relations

Desflurane in modern anaesthetic practice: walking on thin ice(caps)?

Research output: Contribution to journalJournal articlepeer-review

Published

Standard

Desflurane in modern anaesthetic practice : walking on thin ice(caps)? / Shelton, C.L.; Sutton, R.; White, S.M.

In: British Journal of Anaesthesia, Vol. 125, No. 6, 01.12.2020, p. 852-856.

Research output: Contribution to journalJournal articlepeer-review

Harvard

APA

Vancouver

Author

Shelton, C.L. ; Sutton, R. ; White, S.M. / Desflurane in modern anaesthetic practice : walking on thin ice(caps)?. In: British Journal of Anaesthesia. 2020 ; Vol. 125, No. 6. pp. 852-856.

Bibtex

@article{9b676a70377042bdb98e05ef0a06bb4b,
title = "Desflurane in modern anaesthetic practice: walking on thin ice(caps)?",
abstract = "The third-generation volatile anaesthetic agents desflurane and sevoflurane were introduced into clinical practice in the 1990s in response to the perceived need for rapid return of consciousness after ambulatory surgery. Initially marketed by two competing pharmaceutical companies, their relative merits have been debated for three decades. Of the two, desflurane has a lower solubility in blood and therefore the fastest offset, providing a rapid emergence, which is more notable in obese patients and after prolonged anaesthesia. Furthermore, some authorities (including the US Food and Drug Administration [FDA]) have deemed desflurane to be more suitable than sevoflurane for low-flow anaesthesia, as it undergoes only negligible metabolism and minimal reaction with soda lime. However, desflurane has several well-known disadvantages, including a pungent odour (making it a respiratory irritant), lower potency, and environmental impacts related to its manufacture, administration, and discharge into the atmosphere, calling into question its continued use as a general anaesthetic agent.",
keywords = "environmental impact, hypotension, intraoperative complications, perioperative medicine, public health, sustainability, volatile anaesthetics",
author = "C.L. Shelton and R. Sutton and S.M. White",
note = "This is the author{\textquoteright}s version of a work that was accepted for publication in British Journal of Anaesthesia. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in British Journal of Anaesthesia, 125, 6, 2020 DOI: 10.1016/j.bja.2020.09.013",
year = "2020",
month = dec,
day = "1",
doi = "10.1016/j.bja.2020.09.013",
language = "English",
volume = "125",
pages = "852--856",
journal = "British Journal of Anaesthesia",
issn = "0007-0912",
publisher = "ELSEVIER SCI LTD",
number = "6",

}

RIS

TY - JOUR

T1 - Desflurane in modern anaesthetic practice

T2 - walking on thin ice(caps)?

AU - Shelton, C.L.

AU - Sutton, R.

AU - White, S.M.

N1 - This is the author’s version of a work that was accepted for publication in British Journal of Anaesthesia. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in British Journal of Anaesthesia, 125, 6, 2020 DOI: 10.1016/j.bja.2020.09.013

PY - 2020/12/1

Y1 - 2020/12/1

N2 - The third-generation volatile anaesthetic agents desflurane and sevoflurane were introduced into clinical practice in the 1990s in response to the perceived need for rapid return of consciousness after ambulatory surgery. Initially marketed by two competing pharmaceutical companies, their relative merits have been debated for three decades. Of the two, desflurane has a lower solubility in blood and therefore the fastest offset, providing a rapid emergence, which is more notable in obese patients and after prolonged anaesthesia. Furthermore, some authorities (including the US Food and Drug Administration [FDA]) have deemed desflurane to be more suitable than sevoflurane for low-flow anaesthesia, as it undergoes only negligible metabolism and minimal reaction with soda lime. However, desflurane has several well-known disadvantages, including a pungent odour (making it a respiratory irritant), lower potency, and environmental impacts related to its manufacture, administration, and discharge into the atmosphere, calling into question its continued use as a general anaesthetic agent.

AB - The third-generation volatile anaesthetic agents desflurane and sevoflurane were introduced into clinical practice in the 1990s in response to the perceived need for rapid return of consciousness after ambulatory surgery. Initially marketed by two competing pharmaceutical companies, their relative merits have been debated for three decades. Of the two, desflurane has a lower solubility in blood and therefore the fastest offset, providing a rapid emergence, which is more notable in obese patients and after prolonged anaesthesia. Furthermore, some authorities (including the US Food and Drug Administration [FDA]) have deemed desflurane to be more suitable than sevoflurane for low-flow anaesthesia, as it undergoes only negligible metabolism and minimal reaction with soda lime. However, desflurane has several well-known disadvantages, including a pungent odour (making it a respiratory irritant), lower potency, and environmental impacts related to its manufacture, administration, and discharge into the atmosphere, calling into question its continued use as a general anaesthetic agent.

KW - environmental impact

KW - hypotension

KW - intraoperative complications

KW - perioperative medicine

KW - public health

KW - sustainability

KW - volatile anaesthetics

U2 - 10.1016/j.bja.2020.09.013

DO - 10.1016/j.bja.2020.09.013

M3 - Journal article

VL - 125

SP - 852

EP - 856

JO - British Journal of Anaesthesia

JF - British Journal of Anaesthesia

SN - 0007-0912

IS - 6

ER -